FY2029 Earnings Estimate for CLRB Issued By Roth Capital

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Roth Capital issued their FY2029 earnings per share estimates for shares of Cellectar Biosciences in a note issued to investors on Thursday, March 13th. Roth Capital analyst J. Aschoff anticipates that the biopharmaceutical company will post earnings of $0.21 per share for the year. The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($1.59) per share.

Several other equities research analysts have also recently weighed in on CLRB. LADENBURG THALM/SH SH assumed coverage on Cellectar Biosciences in a research report on Thursday, December 5th. They set a “buy” rating and a $13.00 price target on the stock. StockNews.com assumed coverage on Cellectar Biosciences in a research report on Tuesday. They set a “sell” rating on the stock. Finally, Oppenheimer reiterated a “market perform” rating on shares of Cellectar Biosciences in a research report on Wednesday, December 11th.

Cellectar Biosciences Stock Performance

Shares of Cellectar Biosciences stock opened at $0.38 on Monday. Cellectar Biosciences has a 52-week low of $0.22 and a 52-week high of $4.17. The stock’s 50-day simple moving average is $0.29 and its 200 day simple moving average is $1.13. The stock has a market capitalization of $17.38 million, a P/E ratio of -0.22 and a beta of 0.96.

Institutional Investors Weigh In On Cellectar Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of CLRB. Squarepoint Ops LLC bought a new position in shares of Cellectar Biosciences in the fourth quarter worth approximately $156,000. Bank of America Corp DE increased its position in shares of Cellectar Biosciences by 25.3% in the fourth quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 41,704 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Cellectar Biosciences by 687.3% in the fourth quarter. JPMorgan Chase & Co. now owns 182,403 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 159,234 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Cellectar Biosciences by 3.3% in the third quarter. Geode Capital Management LLC now owns 352,452 shares of the biopharmaceutical company’s stock worth $754,000 after purchasing an additional 11,266 shares during the last quarter. Finally, Oppenheimer & Co. Inc. bought a new position in shares of Cellectar Biosciences in the third quarter worth approximately $27,000. 16.41% of the stock is currently owned by institutional investors.

About Cellectar Biosciences

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.